Tokyo, Japan, December 16, 2010 -- Otsuka Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd. announced today that certain of the defendants in the patent litigation concerning Otsuka's substance patent covering aripiprazole, the active ingredient in Abilify^®, have filed notices of appeal to the U.S. Court of Appeals for the Federal Circuit challenging the November 15, 2010 Final Judgment of the U.S. District Court for the District of New Jersey. The defendants named in the notices of appeal are Teva Pharmaceuticals USA, Inc. and other four companies.